Back to Authors

Semenkovich, Nicholas P

0000-0001-5266-6734

Mayo Clinic

Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin.

Citations 3

Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Hashmi, Ayesha , Linford, Jessica , Chauhan, Pradeep S, Parikh, K, Pillai, Malvika , Guittar, John , Ben-Shachar, Rotem , Patel, Jyoti , Nimeiri, Halla , Bergsagel, Matteo , Park, S, Olivier, Kenneth R. , Owen, Dawn , Lee, K.N. , Morgensztern, Daniel, Robinson, Clifford G, Bergom, Carmen , Samson, Pamela , Pellini, B., Vlacich, Gregory , Chaudhuri, Aadel A, Chauhan, Pradeep S. , Ben‐Shachar, Rotem , Chauhan, Pradeep S , Parikh, Kaushal , Patel, Jyoti , Semenkovich, Nicholas P , Park, Sean S , Owen, Dawn , Routman, David M , Lee, Katie N , Sherry, Alexander D , Mansfield, Aaron S , Morgensztern, Daniel , Govindan, Ramaswamy , Robinson, Clifford , Bergom, Carmen , Waqar, Saiama N , Samson, Pamela P , Pellini, Bruna , Vlacich, Gregory R , Chaudhuri, Aadel A , Patel, Jyoti D. , Semenkovich, Nicholas P. , Routman, David M. , Sherry, Alexander D. , Mansfield, Aaron S. , Morgensztern, Daniel , Govindan, Ramaswamy , Pellini, Bruna , Chaudhuri, Aadel A.

Clinical Cancer Research | April 30, 2026 | Volume: 32 | Issue: 14 | Pages: 2945-2956

10.1158/1078-0432.ccr-25-4983 Get It

Abstract Purpose: Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT). Experimental Design: In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309). Results: Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts. Conclusions: Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
Abstract 153: High-resolution profiling of the tumor microenvironment with spatial ecotypes
Brown, Erin L. , Jeon, Hyun Soo , Semenkovich, Nicholas P. , Schwab, Janella C. , Sachs, Chloe M., Gungoren, Bilge , Qaium, Faridi , Mudd, Jacqueline L. , Cai, Qingyuan , Bacchiocchi, Antonella , Halaban, Ruth , Chaudhuri, Aadel A., Semenkovich, Nicholas P , Zhang, Wubing , Usmani, Abul , Earland, Noah , Alahi, Irfan , Steen, Chloé Beate , Harris, Peter K , Fields, Ryan C. , Sznol, Mario , Chen, David Y. , Chaudhuri, Aadel A. , Newman, Aaron M.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 153-153

10.1158/1538-7445.am2025-153 Get It

Background: Multicellular programs in the tumor microenvironment (TME) drive cancer pathogenesis and response to therapy but remain challenging to identify and profile clinically. Here, we present Spatial EcoTyper, a multimodal machine learning framework for large-scale profiling of spatially dependent cell states and multicellular ecosystems, termed spatial ecotypes (SEs). Methods and Findings: By integrating five million single-cell and spot-level spatial transcriptomes from 10 diverse human neoplasms, including carcinomas and melanomas, we identified a rich tapestry of conserved regional plasticity across nine TME cell types. We then applied Spatial EcoTyper to deeply dissect these data, revealing nine novel SEs with broad conservation - each with unique biology, TME cell states, geospatial features, and clinical outcome associations. SEs were linked to specific biogeographic domains, including the tumor core, margin, and adjacent stroma, and were remarkably well-validated in 235 held-out tumor samples profiled by either single-cell RNA sequencing, sequencing-based spatial transcriptomics (10x Visium), or high-resolution imaging-based spatial transcriptomics (Vizgen MERSCOPE and NanoString CosMx). By deconvolving SEs from over 1,200 bulk tumor RNA-seq profiles, we discovered striking associations between SE levels and response to immune checkpoint inhibitors (ICIs), outperforming nearly 40 potential correlates of ICI response, including previously described signatures of tertiary lymphoid structures and tumor tissue PD-L1 expression. Notably, baseline levels of a proinflammatory SE - localized to the tumor core and defined by a hub of unique T cell, macrophage, fibroblast, and endothelial cell states - strongly forecasted ICI benefit, while another SE - localized to the tumor margin and defined by myofibroblast and hypoxia-associated endothelial cell states - portended ICI resistance. Conclusion: Our data reveal fundamental units of TME organization and demonstrate a platform for large-scale profiling of spatial cellular ecosystems in any tissue, with implications for improved forecasting of immunotherapy response and the development of novel therapeutic strategies. Citation Format: Wubing Zhang,Erin L. Brown,Abul Usmani,Noah Earland,Hyun Soo Jeon,Irfan Alahi,Nicholas P. Semenkovich,Janella C. Schwab,Chloé B. Steen,Chloe M. Sachs,Bilge Gungoren,Faridi Qaium,Peter K. Harris,Jacqueline Mudd,Qingyuan Cai,Antonella Bacchiocchi,Ryan C. Fields,Mario Sznol,Ruth Halaban,David Y. Chen,Aadel A. Chaudhuri,Aaron M. Newman. High-resolution profiling of the tumor microenvironment with spatial ecotypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 153.
Advancing Precision Equity With Multicancer Detection Liquid Biopsies
Semenkovich, Nicholas P. , Chaudhuri, Aadel A. , Semenkovich, Nicholas P , Agarwal, Gautam

JAMA Oncology | June 27, 2024 | Volume: 10 | Issue: 8 | Pages: 1023

10.1001/jamaoncol.2024.1860 Get It

This Viewpoint discusses the clinical and socioeconomic potential of multicancer detection liquid biopsies.